high mobility group nucleosomal binding domain 2 pseudogene 18Genealiases: []
Q-omics provides the consensus-scored HMGN2P18 profile across patient tissues and cancer cell-line models. HMGN2P18 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, HMGN2P18 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, HMGN2P18 RNA expression shows 7,682 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight THCA, KICH, and ACC as cancer lineages where HMGN2P18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN2P18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN2P18 survival associations across molecular data types. HMGN2P18 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN2P18 RNA expression–survival associations across cancer types. High HMGN2P18 expression shows unfavorable associations in HNSC, READ, LIHC and PAAD, but favorable associations in THCA and SKCM. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for HMGN2P18 RNA expression.
This table summarizes HMGN2P18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for HMGN2P18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN2P18 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC and HNSC. The KICH box plot shows higher HMGN2P18 RNA expression in normal versus tumor tissue (log2 FC = −0.246, t-test p < 0.001).
This table shows molecular features associated with HMGN2P18 in patient tissues and cancer cell lines. In patient samples, HMGN2P18 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
